Please login to the form below

Not currently logged in
Email:
Password:

neurogenics

This page shows the latest neurogenics news and features for those working in and with pharma, biotech and healthcare.

Merck buys cough drug developer Afferent for $1.25bn

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications. ... These receptors seem to become more common after nerve injury or inflammation, and drugs that block them are thought to have potential in a broad range of

Latest news

  • Lundbeck agrees $658m deal to buy Chelsea Therapeutics Lundbeck agrees $658m deal to buy Chelsea Therapeutics

    Chelsea's marketed product - Northera (droxidopa) - was given a green light by the US FDA in February as the first drug specifically approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a

  • FDA approves Chelsea's rare blood pressure drug FDA approves Chelsea's rare blood pressure drug

    The Food and Drug Administration (FDA) backed Northera capsules (droxidopa) to treat neurogenic orthostatic hypotension (NOH), a chronic drop in blood pressure that is found in patients with Parkinson's disease, ... People with neurogenic orthostatic

  • FDA panel backs Chelsea's Northera for rare disease FDA panel backs Chelsea's Northera for rare disease

    The regulator's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16 to 1 in favour of the approval of Northera (droxidopa) to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients ... with an underlying neurogenic disorder,

  • Positive opinion for Allergan's NDO treatment

    A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO). ... NDO results from neurogenic bladder, due to stable sub-cervical spinal cord injury (SCI) or multiple sclerosis (MS).

  • Allergan in $600m Botox settlement

    The company is currently conducting phase II clinical trials as part of an effort to win marketing approval for neurogenic and idiopathic overactive bladder.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    in development for the treatment of neurogenic conditions, such as chronic cough.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).

  • Pharma deals during May 2014 Pharma deals during May 2014

    Chelsea has the recently FDA-approved droxidopa, the first and only symptomatic treatment for neurogenic orthostatic hypotension ready for launch later this year.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics